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ultrasound examination of the abdomen showed hepa-
tomegaly with multiple hypoechoic lesions (maximal dia-
meter 5 cm) surrounded by a hyperechoic border (Figure 1).
Hepatitis B an C serology were negative. Alcohol abuse was
denied.
QUESTIONS
1. What is your clinical diagnosis?
2. How are you going to confirm your diagnosis?
3. How are you going to treat the patient?
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CASE REPORT
A 41-year-old Indian man with recurrent squamous cell lung
carcinoma was evaluated for left anterior chest wall fistula tract.
Eight weeks earlier, he underwent an extensive excision of the
chest wall, 6th and 7th ribs, and prolene mesh placement.
He complained of severe pain extending from the left
anteriolateral chest wall and ipsilateral breast area and denied
Figure1 Computed tomography scanof chest
without intravenous contrast shows a circum-
ferential thickening of the left pleura and ad-
joining pericardium (black arrows). Localised
left pneumothorax and pneumopericardium
suggest communicationwith the chest wall fis-
tula tract (white arrow heads).
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having cough, dyspnea, weight loss, fever or night sweats.
On examination, a markedly tender left gynecomastia, and
a friable, indurated mass extending from the opening of the
inframammary fistula tract was observed. The aerobic, anaero-
bic, fungal and mycobacterial stains and cultures of the copious
serosangious discharge from the fistula tract were negative.
Laboratory studies showed the following: white blood cell
count 9.7 000/mL, hemoglobin 12.0 g/dL, platelets 156 000/
mm3, lactate dehydrogenase 156 U/L, aspartate aminotransfer-
ase 25 U/L, albumin 4.4 g/dL, and erythrocyte sedimentation
rate 64 mm H2O/h. Left circumferential pleural and pericardial
thickening were observed on computed tomography scan of
the chest, and accompanying effusions were inconspicuous
(Figure 1).
Owing to primary surgical wound dehiscence, an initial
debridement revealed acid-fast bacilli in surgical wound speci-
mens. Treatment for Mycobacterium tuberculosis was initiated and
continued. All cultures, including blood, deep wound and
respiratory tract, remained sterile. There was no evidence of
cancer recurrence or metastasis.
QUESTIONS
1. Is this postoperative chest wall and intrathoracic infection
due to M. tuberculosis?
2. What is the probable source of this infection?
3. Is this infection more severe in patients with compromised
immune systems?
4. Are mycobacterial infections due to different species
histopathologically distinguishable?
5. Is surgical removal of the infected foreign material neces-
sary in this setting?
6. What are the optimal antimicrobial agents to use while
waiting for drug susceptibility results?
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